Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [906]

MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II...

Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA

MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-III NSCLC ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )

Cemiplimab plus ipilimumab for advanced NSCLC

Prof Byoung Yong Shim - The Catholic University of Korea, Suwon, South Korea

Cemiplimab plus ipilimumab for advanced NSCLC ( Prof Byoung Yong Shim - The Catholic University of Korea, Suwon, South Korea )

Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small...

Dr Erminia Massarelli - City of Hope, Duarte, USA

Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small cell lung cancer ( Dr Erminia Massarelli - City of Hope, Duarte, USA )

Incorporating KRAS as a novel biomarker: Challenges and opportunities

Prof Ales Ryska - Charles University, Prague, Czech Republic

Incorporating KRAS as a novel biomarker: Challenges and opportunities ( Prof Ales Ryska - Charles University, Prague, Czech Republic )

Real world data and diagnostics in patients with NSCLC with EGFR exon 20...

Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio...

Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions ( Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio Passaro )

Durvalumab following radiotherapy in patients with unresectable, stage 3 NSCLC...

Prof Andrea Filippi - University of Pavia, Pavia, Italy

Durvalumab following radiotherapy in patients with unresectable, stage 3 NSCLC ineligible for chemotherapy ( Prof Andrea Filippi - University of Pavia, Pavia, Italy )

OncoAlert and ecancer weekly roundup for March 01 - 06, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly roundup for March 01 - 06, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Managing the treatment of NSCLC patients during the COVID-19 pandemic (ES)

Dr Giuseppe Giaccone, Dr Marina Garassino

Managing the treatment of NSCLC patients during the COVID-19 pandemic (ES) ( Dr Giuseppe Giaccone, Dr Marina Garassino )

Managing the treatment of NSCLC patients during the COVID-19 pandemic (IT)

Dr Giuseppe Giaccone, Dr Marina Garassino

Managing the treatment of NSCLC patients during the COVID-19 pandemic (IT) ( Dr Giuseppe Giaccone, Dr Marina Garassino )

Managing the treatment of NSCLC patients during the COVID-19 pandemic (DE)

Dr Giuseppe Giaccone, Dr Marina Garassino

Managing the treatment of NSCLC patients during the COVID-19 pandemic (DE) ( Dr Giuseppe Giaccone, Dr Marina Garassino )

Managing the treatment of NSCLC patients during the COVID-19 pandemic (FR)

Dr Giuseppe Giaccone, Dr Marina Garassino

Managing the treatment of NSCLC patients during the COVID-19 pandemic (FR) ( Dr Giuseppe Giaccone, Dr Marina Garassino )

Reducing the risk of contracting COVID-19 in patients with NSCLC (IT)

Dr Giuseppe Giaccone, Dr Neal Navani, Professor Eric Lim

Reducing the risk of contracting COVID-19 in patients with NSCLC (IT) ( Dr Giuseppe Giaccone, Dr Neal Navani, Professor Eric Lim )

More from ecancer